| Population |
ICER (ICERAB) |
| ICER |
Median Bootstrapped ICER |
Bootstrap 95% Percentiles |
| Incremental Cost per PCa Avoided |
|
|
|
| Biopsy |
$18.76 |
$21.69 |
$14.96 to $35.21 |
| North America |
$119.18 |
$134.80 |
$63.73 to $734.72 |
| Baseline PSA < 4.9 ng/mL |
$53.77 |
$67.87 |
$42.27 to $150.54 |
| Baseline PSA ≥ 4.9 to < 6.8 ng/mL |
$71.38 |
$79.09 |
$41.91 to $330.94 |
| Baseline PSA ≥ 6.8 ng/mL |
$47.09 |
$51.50 |
$24.61 to $148.69 |
| Incremental Cost per QALY |
|
|
|
| Biopsy |
$26 515.79 |
$26 178.53 |
$20 121.79 to $35 817.95 |
| North America |
$51 780.04 |
$49 144.28 |
$29 239.45 to $190 938.52 |
| Baseline PSA < 4.9 ng/mL |
$33 257.08 |
$33 286.40 |
$22 709.88 to $56 973.40 |
| Baseline PSA ≥ 4.9 to < 6.8 ng/mL |
$24 537.55 |
$24 914.72 |
$16 446.11 to $42 019.95 |
| Baseline PSA ≥ 6.8 ng/mL |
$22 391.29 |
$22 621.86 |
$12 805.91 to $47 302.07 |
ICER = incremental cost-effectiveness ratio; PCa = prostate cancer; PSA = prostate-specific antigen; QALY = quality-adjusted life-year.